Drug Regimen New Option for Some Endometrial Cancers Free

The FDA has approved a durvalumab (Imfinzi; AstraZeneca)–chemotherapy regimen to treat certain endometrial cancers—specifically those that are primary advanced or recurrent cancers that are mismatch repair (MMR) deficient. Efficacy was evaluated in the DUO-E trial, in which patients with primary advanced or recurrent endometrial cancer were randomly assigned to receive durvalumab with carboplatin plus paclitaxel followed by durvalumab maintenance therapy; a placebo with carboplatin plus paclitaxel followed by a placebo alone; or another investigational combination regimen. A statistically significant improvement in progression-free survival (PFS) was observed in the overall population receiving durvalumab, but the improvement was primarily attributed to patients’ MMR deficiency status. Among 95 patients with MMR-deficient tumors, the median PFS was not reached in the durvalumab arm and was 7 months in the placebo arm.